Alzheimer Drug Reduces Amyloid Plaques In Phase 2 Trial, Creates Excitement
A new Alzheimer’s drug, called BAN2401 reduced amyloid plaques in Alzheimer’s patients during Phase 2 clinical trials. Partnering drug manufacturers, Biogen and Eisai announced this exciting news last week. The long losing streak in finding an Alzheimer’s drug cure may be over. This Phase 2 clinical trial which lasted 18 months, showed BAN240 …